Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates
Nektar (NKTR) delivered earnings and revenue surprises of 21.74% and 55.24%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
The Washington Post3h
Nektar: Q3 Earnings Snapshot
SAN FRANCISCO — SAN FRANCISCO — Nektar Therapeutics (NKTR) on Thursday reported a loss of $37.1 million in its third quarter. On a per-share basis, the San Francisco-based company said it had a loss ...
Le Lézard3h
Nektar Therapeutics Reports Third Quarter 2024 Financial Results
Nektar Therapeutics today reported financial results for the third quarter ended September 30, 2024. Cash and investments ...
Nektar presents late-breaking results from Phase 2 Study of NKTR-255
Therapeutics and collaborators at The University of Texas MD Anderson Cancer Center presented late-breaking results from a Phase ...
FiercePharma10h
Biologics CDMO Avid Bioservices to go private with $1.1B sale to Ampersand, GHO Capital
Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...
MM&M11h
Rx Rundown: Avid Biosciences, Novo Nordisk, Zealand Pharma and more
Nektar Therapeutics is selling its Huntsville, Alabama, manufacturing plant and reagent supply business to private equity firm Ampersand Capital Partners for $90 million. Ascendis Pharma and Novo ...